TRT Blood Work Explained: What Labs to Monitor on Testosterone Therapy

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

This article provides a comprehensive guide to TRT Blood Work Explained: What Labs to Monitor on Testosterone Therapy, covering essential aspects for practitioners and individuals. It delves into specific protocols and considerations for effective use.

The Importance of Blood Work in TRT

Testosterone Replacement Therapy (TRT) is a powerful intervention for men with symptomatic hypogonadism, but its safe and effective long-term management hinges on meticulous monitoring through regular blood work. Blood tests provide critical insights into the body's response to exogenous testosterone, allowing clinicians to optimize dosing, identify potential side effects early, and ensure overall patient safety. Without consistent lab monitoring, patients risk experiencing suboptimal benefits, developing preventable complications, or overlooking serious underlying health issues. A comprehensive panel of blood tests is required at baseline, during the initial titration phase, and periodically throughout the course of therapy [1].

Key Blood Tests to Monitor on TRT

Several key laboratory parameters should be routinely assessed in men undergoing TRT:

  1. Total Testosterone:
    • Purpose: The primary measure to ensure testosterone levels are within the desired physiological range, typically aiming for the mid-normal range (e.g., 400-700 ng/dL or 13.8-24.3 nmol/L).
    • Timing: For injectable testosterone, blood should be drawn at mid-cycle (e.g., 3.5 days after a weekly injection) to assess average levels, or at trough (just before the next injection) to ensure levels don't drop too low. For gels/creams, blood is typically drawn 2-4 hours after application.
    • Interpretation: Levels too low may indicate insufficient dosing; levels too high (e.g., >1000 ng/dL) suggest over-dosing and increase the risk of side effects.

  2. Free Testosterone:
    • Purpose: Measures the unbound, biologically active portion of testosterone. Can be more indicative of tissue availability and symptom resolution than total testosterone alone.
    • Interpretation: Should generally be in the upper quartile of the normal reference range.

  3. Estradiol (E2):
    • Purpose: Testosterone is converted to estradiol by the aromatase enzyme. Elevated E2 can lead to gynecomastia, fluid retention, and mood disturbances.
    • Interpretation: While there's no universally agreed-upon optimal E2 range on TRT, levels typically below 40-50 pg/mL are desirable. High E2 often correlates with higher testosterone doses and body fat.
    • Management: If E2 is high and symptomatic, dose reduction, increased injection frequency, or an aromatase inhibitor (e.g., anastrozole 0.25-0.5mg once or twice weekly) may be considered.

  4. Hematocrit (HCT) and Hemoglobin (HGB) (part of CBC):
    • Purpose: To monitor for erythrocytosis, an increase in red blood cell count, which can increase blood viscosity and the risk of blood clots.
    • Interpretation: A hematocrit above 52% is generally considered a threshold for intervention.
    • Management: Dose reduction, increased injection frequency, or therapeutic phlebotomy (blood donation) are common interventions.

  5. Prostate-Specific Antigen (PSA):
    • Purpose: A marker for prostate health and prostate cancer screening. TRT can stimulate prostate growth and potentially accelerate the growth of pre-existing prostate cancer.
    • Monitoring: Baseline PSA, then at 3-6 months, and annually thereafter, especially in men over 40-50.
    • Interpretation: A significant rise in PSA (e.g., >0.75 ng/mL in one year) or levels above age-specific norms warrant further investigation by a urologist.

  6. Lipid Panel and Glucose:
    • Purpose: To assess cardiovascular and metabolic health. TRT can sometimes have mixed effects on lipids, and monitoring is important.
    • Interpretation: Should be within healthy ranges.

  7. LH (Luteinizing Hormone) and FSH (Follicle-Stimulating Hormone):
    • Purpose: While often suppressed by exogenous testosterone, monitoring them can help confirm the suppression of endogenous production and assess pituitary function if HCG is used.

    8. Monitoring Schedule

    A typical monitoring schedule involves blood work at baseline, then at 4-6 weeks after initiating TRT or any dose change, then every 3-6 months for the first year, and annually thereafter once stable. This systematic approach ensures that TRT is both effective and safe for the long term [2].

    References

    • [1] Bhasin, S., et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744.
    • [2] Khera, M., et al. (2016). A New Definition of Hypogonadism and a Re-evaluation of the Current Practice of Testosterone Replacement Therapy. Journal of Sexual Medicine, 13(5), 772-785.